Papilloma Pseudovirus for Detection and Therapy of Tumors
Posted Jan 31 2008 4:00pm
Description of Invention: There is extensive literature on the use of viral vectors, particularly those based on the adenovirus and AAV, to increase the potency of anti-tumor gene therapy. However, these approaches have had limited success because of limited anti-tumor effects and unacceptable toxicity. This invention describes the use of papillomavirus pseudoviruses (PsV) as a gene transfer technology and a tumor diagnostic method. Preliminary studies showed that PsV bind to cells that were transplanted with human ovarian tumor (Shin-3) while normal tissues were not affected. PsV does not infect several other normal intact tissues but continues to selectively infect additional cell types that are damaged. Additionally, the inventors have constructed oligoT PsV vectors that can be engineered to express certain cytotoxic genes to induce tumor regression and simultaneous increase human papilloma virus’ immunogenicity. This technology could be an effective anti-tumor therapy because it has shown increased infection of compromised cells with an inability to infect normal cells thereby reducing potential toxicity to patients. In addition to a potential anti-cancer therapeutic, this technology could also be used as a diagnostic tool in the detection of tumor masses. Detection can be achieved through the use of fluorescent dye coupled particles of PsV that have preferential binding to tumor tissues and not normal tissues.
Method to treat and selectively target cancer with limited toxicity.
Method to accurately diagnose cancer.
Anti-tumor therapeutic vaccines.
Anti-tumor cytoxic gene therapy constructs.
Development Status: The technology is currently in the pre-clinical stage of development.
CB Buck et al. Generation of HPV pseudovirions using transfection and their use in neutralization assays. Methods Mol Med. 2005;119:445-462. [ PubMed abs ]
CB Buck et al. Efficient intracellular assembly of papillomaviral vectors. J Virol. 2004 Jan;78(2):751-757. [ PubMed abs ]
Licensing Status: Available for licensing.
Portfolios: Cancer Cancer - Diagnostics Cancer - Therapeutics Cancer - Research Materials Gene Based Therapies Gene Based Therapies - Therapeutics Gene Based Therapies - Research Materials Gene Based Therapies - Other
For Additional Information Please Contact: Jennifer Wong NIH Office of Technology Transfer 6011 Executive Blvd. Suite 325, Rockville, MD 20852 United States Email: firstname.lastname@example.org Phone: 301-435-4633 Fax: 301-402-0220